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ABSTRACT 
 
Herbal supplements are not governed by the same regulations as prescription drugs, we hy-
pothesize that the content of their active ingredients may vary largely among different manu-
facturers. This may produce variable therapeutic outcomes. This study aims to examine this 
hypothesis on commonly used herbal supplements among cancer patients. CYP1A2 has been 
implicated in the activation of many carcinogens and alteration in its activity may be a mech-
anism associated with the protective effect of herbal products. Activity of human CYP1A2 
was used to determine the effect of four herbal supplements of different brands, namely, black 
cohosh (BC), ginseng, grape seed extract (GSE) and green tea extract (GTE). The herbal con-
tent was extracted with methanol, and extract aliquots were used to determine their effect on 
CYP1A2. Human liver microsomes, the CYP1A2 probe (7-ethoxyresorufin) and NADPH in 
buffer were incubated with and without herbal extract. Metabolite (resorufin) formation was 
monitored by HPLC. Seven BC products caused a mild inhibition of CYP1A2, ranging from 
2.4 % by GNC Plus to 21.9 % by Nature’s Resource. Among nine ginseng products tested, the 
inhibitory effect varied from 4.2 % by Imperial to 44.6 % by Solarays. The effect of nine GSE 
brands also varied, ranging from 1.7 % (Country Life) to 26.5 % (Veg Life). Of twelve GTE 
products, the inhibitory effect varied from 2.9 % by Henry’s to 46.6 % by GNC Plus. It ap-
pears that the inhibition of selected herbal supplements on CYP1A2 activity varies considera-
bly among different brands of the products. This may be due to variations in the herbal prod-
ucts’ active ingredients content.  
 
Keywords: dietary supplements, CYP1A2, black cohosh, ginseng, grape seed extract, green 
tea extract, drug interaction 
 
 
                                                 
♦ This work was presented in part at the American Association of Pharmaceutical Scientists (AAPS) Annual 
Meeting, October 29-November 2, 2006, San Antonio, Texas, USA. 
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INTRODUCTION 
Dietary supplements are commonly 
consumed by patients worldwide. In the 
United States, approximately 25 % of peo-
ple use dietary supplements (Gurley et al. 
2005a). Many of these supplements are 
herbal in nature (Wargovich, 2001). It is 
worthy of note that the rate of herbal usage 
is much greater in cancer patients, in some 
cases, up to 50 % of patients treated in 
cancer centers (Pierce et al., 2002; Rich-
ardson et al., 2000; Rock et al., 2004; 
Wargovich, 2001; Wargovich et al., 2010).  
Cytochrome P450 (CYP) enzymes are 
responsible for detoxification of a wide 
range of foreign compounds including 
drugs, environmental pollutants, and car-
cinogens. Most chemical carcinogens re-
quire metabolic activation by phase I en-
zymes (e.g., CYP) and detoxification by 
conjugation phase II enzymes (e.g., gluta-
thione S-transferase and glucuronosyl 
transferase). The coordinated expression 
and regulation of phase I and phase II me-
tabolizing enzymes and their metabolic 
balance may be an important host factor in 
determining susceptibility to cancer (Guen-
gerich 1999; Sato et al., 2000). There may 
be several underlying mechanisms of 
chemoprevention by herbal supplements. 
The herbal supplements not only possess 
good reactive oxidative free-radical scav-
enging abilities, but they may also be ca-
pable of inhibiting or inducing phase I and 
phase II enzymes. CYP1A1 plays an im-
portant role in the activation of carcino-
gens such as polycyclic aromatic hydro-
carbons (PAHs), heterocyclic amines, ni-
trosamines and mycotoxins. CYP1A2, 
which is induced in the human liver by 
cigarette smoking, has been implicated in 
the activation of a number of carcinogens 
(Guengerich, 1999; Sato et al., 2000). 
CYP1A2 has been strongly involved in the 
activation of heterocylic aromatic amine 
cooked-food carcinogens, such as 2-
amino-3,8-dimethylimidazo[4,5-f]quinoxa-
line (MeIQx) and 2-amino-3-methylimi-
dazo[4,5-f]quinoline (IQ) (Murray et al., 
1993). It has been shown that various fla-
vonoids (e.g., apigenin, chrysin and quer-
cetin) are capable of reducing the for-
mation of DNA adducts from PAH by in-
hibition of CYP1A1 (Lautraite et al., 
2002). Alterations of CYP activity by phy-
tochemical ingredients of herbal products 
may be one of the mechanisms associated 
with a protective effect against cancer.  
Black cohosh (Cimicifuga racemosa) is 
a shrub-like plant native to the eastern for-
ests of North America. It has been used by 
Native Americans for menopausal symp-
toms, pre-menstrual discomfort, dysmenor-
rheas and for many other indications. Sev-
eral preparations of black cohosh are high-
ly recommended as a safe and effective 
natural remedy for menopausal symptoms. 
Women who have been advised by their 
physicians to avoid hormone replacement 
therapy (HRT), who are at high risk for 
breast cancer or have discontinued HRT 
after a diagnosis of breast cancer currently 
use black cohosh as treatment (Rockwell et 
al., 2005). The root of ginseng (Panax gin-
seng C.A. Meyer) has traditionally been 
used in East Asia over 2000 years for the 
treatment of cancer, cardiovascular diseas-
es, hypertension, diabetes mellitus and liv-
er dysfunction (Helms, 2004). Ginseng 
was the second highest selling herbal sup-
plement in the United States in 2000, with 
gross retail sales of $ US 62 million (Blu-
menthal, 2001). Grape seed extract is one 
of the top-selling herbal supplements in the 
United States (Sparreboom et al., 2004). 
Commercial preparations of grape seed 
polyphenols, widely referred to as “grape 
seed extract (GSE)”, are standardized to 
contain 95 % procyanidins. GSE prepara-
tions are marketed in the USA as a dietary 
supplement, due to their health benefits, 
particularly the strong antioxidant activity. 
There are several studies reporting that 
GSE could be potential cancer chemopre-
ventive agents (Agarwal et al., 2002; Chen 
et al., 2005; Singletary and Meline, 2001; 
Zhao et al., 1999) and can prevent heart 
attack and skin aging (Bagchi et al., 1997, 
1998; Maffei et al., 1996). Consumption of 
green tea (Camellia sinensis) has been 
claimed to have potential health benefits, 
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such as the prevention of cancer and cardi-
ovascular diseases (Cabrera et al., 2006; 
Yang and Landau, 2000; Yang et al., 2002, 
2006). Green tea extracts are widely used 
as dietary supplements. Green tea and tea 
polyphenols have been investigated exten-
sively because tea polyphenols possess 
strong antioxidant properties and show in-
hibitory activity against carcinogenesis 
(Anger et al., 2005; Maliakal et al., 2011; 
Yang et al., 2006). Since tea is the most 
popular beverage in the world and because 
of the absence of toxicity, tea is an excel-
lent candidate for cancer prevention (Yang 
et al., 2002, 2006).  
Because dietary herbal supplements are 
not subject to the same FDA regulations as 
prescription drugs and over-the-counter 
medications, herbal products generally 
lack quality control and the regulatory 
oversight of therapeutic products. With 
these reasons we hypothesize that the con-
tent of active ingredients in herbal supple-
ments may vary among different manufac-
turers. This difference in the active ingre-
dients may produce variation in therapeutic 
outcomes and the extent of herbal drug in-
teractions. This hypothesis is based on the 
following observations. First, it has been 
reported with a few herbal supplements, 
including St. John’s wort, ginseng and 
ephedra, that the content of active ingredi-
ents varied widely between brands and in 
some cases the content variation was also 
found between batches of the same herbal 
products (Draves and Walker 2003; Gurley 
et al., 2000; Harkey et al., 2001). Second, 
in relation to antioxidant activity of grape 
polyphenols, a correlation existed between 
the antioxidant activity and the content of 
polyphenols in grape seed extracts (Zhao et 
al., 1999). Therefore, the present study 
aimed to investigate this hypothesis with 
regard to commonly used herbal supple-
ments, black cohosh, ginseng, grape seed 
extract and green tea extract. Activity of 
human CYP1A2 was used as a parameter 
to examine the effect of these herbal sup-
plements purchased from many manufac-
turers. 
 
MATERIALS AND METHODS 
Chemicals and dietary supplements 
All chemicals and reagents used were 
of analytical grade. Resorufin, 7-ethoxy-
resorufin and NADPH were purchased 
from Sigma-Aldrich Co. (St. Louis, MO, 
USA). Four different commercial herbal 
supplements namely black cohosh (BC), 
ginseng, grape seed extract (GSE) and 
green tea extract (GTE) were randomly 
purchased from pharmacy stores in Cali-
fornia, USA, during the year 2005. There 
were seven brands of BC, nine brands of 
ginseng, nine brands of GSE and twelve 
brands of GTE products. Details of manu-
facturers and content of each capsule are 
listed in Table 1. 
 
Preparation of human liver microsomes  
A human liver used was obtained from 
a Caucasian male donor aged 50 years who 
had met traumatic death. He was neither 
taking medication nor had significant past 
medical history. The use of human liver 
was approved by the Southern Regional 
Health Authority (Otago) Ethics Commit-
tee, Dunedin, New Zealand. Human liver 
microsomes were prepared by a standard 
differential ultracentrifugation as previous-
ly described (Zhang et al., 1997). 
 
Preparation of herbal supplement meth-
anolic extract 
The content of herbal supplement stud-
ied was determined by weighing the actual 
content in each capsule. This was per-
formed with six replicates (n = 6 capsules). 
The contents from these six capsules were 
combined. The content of an herbal prod-
uct, equivalent to the average content in 
one capsule was extracted with approxi-
mately 80 mL methanol using ultra soni-
cation for 1 hour. The mixture was adjust-
ed to a final volume of 100 mL with meth-
anol. An aliquot of this mixture was then 
centrifuged at 2500 g for 15 min. The su-
pernatant was collected and referred as 
methanolic extract. 
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Table 1: Characteristics of herbal supplements used 
 
Brand Name Manufacturer mg/capsule 
 
Black Cohosh: 
  
GNC Herbal Plus General Nutrition Corp. 50 mg 
GNC Nature's Fingerprint General Nutrition Corp. 540 mg 
Natural Factors Natural Factors, Canada 40 mg 
Nature's Resource Nature's Resource Products 40 mg 
Nature's Way Nature's Way Products, Inc. 540 mg 
Spring Valley IdeaSphere, Inc. 300 mg 
Sundown Sundown, Inc. 540 mg 
   
Ginseng:   
Action Labs Nutraceutical Corp. 250 mg 
GNC General Nutrition Corp. 550 mg 
GNC Herbal Plus General Nutrition Corp. 500 mg 
Imperial Elixir GINCO International 600 mg 
Life Time LifeTime Nutritional Specialties, Inc. 650 mg 
Nature's Resource Nature's Resource Products 250 mg 
Root to Health Root to Health 500 mg 
Solarays Nutraceutical Corp. 535 mg 
Spring Valley Nature's Bounty, Inc. 100 mg 
   
Grape Seed Extract:   
Country Life Country Life  50 mg 
GNC Herbal Plus General Nutrition Corp. 50 mg 
GNC Nature's Fingerprint General Nutrition Corp. 100 mg 
Jarrow Formulas Jarrow Formulas 50 mg 
Loma Linda Market  Loma Linda Wholesome Foods 100 mg 
MRM Metabolic Response Modifiers 120 mg 
Sundown Sundown, Inc. 30 mg 
VegLife Nutraceutical Corp. 100 mg 
Walgreens Finest Natural Walgreen Co. 50 mg 
   
Green Tea Extract:   
Country Life Country Life  300 mg 
GNC Herbal Plus General Nutrition Corp. 150 mg 
GNC Natural Brand General Nutrition Corp. 315 mg 
Henry's Farmers Market Henry's Marketplace 250 mg 
Jarrow Formulas Jarrow Formulas 500 mg 
Natrol Natrol, Inc. 500 mg 
Natural Factors Natural Factors, Canada 300 mg 
Natural Factors Natural Factors, Canada 50 mg 
Nature's Resource Nature's Resource Products 150 mg 
Paradise Herbs Paradise Herbs, Inc. 250 mg 
Rexall Rexall, Inc. 315 mg 
Spring Valley Nature’s Bounty, Inc. 100 mg 
 
 
 
 
CYP1A2 assay procedure 
Aliquots (5 µL) of the herbal methanol-
ic extract were tested for their ability to in-
hibit the metabolism of a CYP1A2 marker 
substrate using an in vitro liver microsomal 
technique. 7-Ethoxyresorufin was used as a 
specific probe substrate for human 
CYP1A2 (Burke et al., 1994). Incubation 
mixtures (0.5 mL) containing human liver 
microsomes (0.1 mg/mL), 7-ethoxy-
resorufin (500 nM) and NADPH (1 mM) in 
phosphate buffer (0.067 M, pH 7.4) were 
incubated with or without (i.e. as control) 
herbal extract (5 µL) at 37 °C for 10 min. 
All experiments were performed in four 
replicates. After incubation, the reaction 
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was terminated by addition of 1 mL cold 
methanol. The mixture was centrifuged and 
the aliquots (30 µL) of supernatant were 
injected onto an HPLC column. Formation 
of the metabolite (resorufin) generated by 
the CYP1A2-mediated reaction was as-
sayed by a reversed-phase HPLC method 
(Hanioka et al., 2000) with fluorescence 
detection. The detection limit of this assay 
was 0.1 nM. The inter- and intra-assay co-
efficient of variation was < 6 % over the 
concentration range of 0.1 to 100 nM.  
 
Statistical analysis  
Results were expressed as mean and 
standard deviation (SD). Data was analyzed 
by a one-way ANOVA, followed by multi-
ple comparisons utilizing Tukey’s test 
(SPSS version 18.0, SPSS Inc., Chicago, 
IL, USA). A p < 0.05 was considered to be 
statistically significant. 
 
RESULTS 
Our preliminary study had demonstrated 
that the methanolic extracts of herbal sup-
plements investigated did not have any 
compounds that interfered with the HPLC 
assay for resorufin (CYP1A2 assay). This 
was confirmed by the results obtained from 
incubation of each herbal supplement ex-
tract with human liver microsomes under 
the same experimental conditions used, 
without CYP1A2 substrate (7-ethoxy-
resorufin). After incubation, none of the 
herbal supplement extracts had peaks inter-
fered with resorufin in the HPLC analysis. 
Results with the seven brands of BC 
product have shown that there was very lit-
tle to mild inhibition of the activity of 
CYP1A2 caused by BC products (Figure 1). 
The inhibitory effect varied from 2.4 % in-
hibition by GNC Plus brand to 21.9 % inhi-
bition by the Natures Resource product. 
The actual activities of CYP1A2 caused by 
all (except GNC Plus brand) BC herbal ex-
tracts were significantly less than the con-
trol value (p < 0.05). The percentage of 
CYP1A2 inhibition produced by BC prod-
ucts did not correlate with the BC herbal 
content claimed in these products (r = 
0.035, p > 0.5). 
 
Figure 1: Effects of different brands of black 
cohosh dietary supplement on the activity of 
CYP1A2. Each bar represents mean (and SD) 
% of inhibition of human CYP1A2 activity, ob-
tained from 4 different measurements. 
 
Nine different brands of ginseng pro-
ducts were tested, two products were shown 
to inhibit the activity of CYP1A2 moderate-
ly while the other seven brands had very 
little effect on the activity of CYP1A2 
(Figure 2). The two ginseng products pro-
ducing moderate inhibition were 100 mg 
Spring Valley (34.1 % inhibition) and 535 
mg Solarays (44.6 % inhibition) brands. 
Overall, the inhibitory effect on CYP1A2 
varied from 4.2 % by Imperial (600 mg) to 
44.6 % by Solarays (535 mg) brand. There 
was no significant correlation between the 
% CYP1A2 inhibition and the contents of 
ginseng (r = -0.234, p > 0.4). For example, 
the Spring Valley ginseng product contain-
ing 100 mg caused CYP1A2 inhibition of 
31.4 %, while GNC Plus (500 mg) ginseng 
inhibited the activity of CYP1A2 by only 
14.2 %. 
Of nine brands of GSE tested, six 
brands caused moderate inhibition of 
CYP1A2 activity, the other three brands 
produced very little inhibition of CYP1A2 
(Figure 3). The inhibitory effect caused by 
GSE ranged from 1.7 % by Country Life 
brand to 26.5 % by VegLife product. Simi-
lar to the other two herbal products men-
tioned above, the inhibitory effects pro-
duced by GSE did not appear to correlate 
with the content of GSE (r = 0.454, p > 
0.1). For instance, among the products con-
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taining 50 mg GSE, the effect varied from 
very little effect (1.7 %) by Country Life to 
moderate inhibition of 23.2 % by GNC Plus 
brand.  
 
Figure 2: Effects of different brands of ginseng 
dietary supplement on the activity of CYP1A2. 
Each bar represents mean (and SD) % of inhi-
bition of human CYP1A2 activity, obtained from 
4 different measurements. 
 
 
Figure 3: Effects of grape seed extract dietary 
supplements with different brands on the activi-
ty of human CYP1A2. Each bar represents 
mean (and SD) % of inhibition of the CYP1A2, 
obtained from 4 different measurements. 
 
Most of green tea extract (GTE) prod-
ucts caused some degree of inhibition of 
CYP1A2. Of twelve brands of GTE stud-
ied, nine brands produced moderate inhibi-
tion of human CYP1A2. However, the in-
hibitory effect produced by GTE varied 
from 2.9 % by Henry’s to 46.6 % by GNC 
Plus GTE (Figure 4). The actual CYP1A2 
activities in the presence of all (except Hen-
ry’s) GTE extracts were significantly less 
than the control value (p < 0.05). However, 
the % inhibition of CYP1A2 produced by 
these products did not correlate (r = -0.191, 
p > 0.5) with the content specified in the 
GTE capsules.  
 
Figure 4: Effects of green tea dietary supple-
ments on human CYP1A2 activity. Each bar 
represents mean (and SD) % inhibition of the 
CYP1A2, obtained from 4 different measure-
ments. 
 
DISCUSSION 
Even though the use of herbal supple-
ments is very common in recent years, there 
is limited information on the safety and ef-
ficacy of herbal products used alone or in 
combination with prescription drugs. Addi-
tional studies are needed to illustrate the 
safety and efficacy of herbal products in 
humans (Green et al., 2001; Haller et al, 
2004; Hamburger et al., 2001; Shi and 
Klotz, 2012). Meanwhile, caution must be 
taken in prescribing drugs to patients who 
take herbal supplements. Also risk and ben-
efit of taking herbal supplements should be 
considered. Patients and health care profes-
sionals must be encouraged to discuss the 
use of herbal products and be well-
informed about the potential interactions 
between herbs and prescription drugs. 
The goal of this study was to clarify 
whether the four herbal supplements, black 
cohosh, ginseng, grape seed extract and 
green tea extract would affect human 
CYP1A2 activity. These herbal supple-
ments are commonly used among cancer 
patients (Pierce et al., 2002; Richardson et 
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al., 2000; Rock et al., 2004; Wargovich, 
2001; Wargovich et al., 2010). Of these 
supplements studied, black cohosh and gin-
seng caused very mild inhibition of 
CYP1A2 whereas green tea and grape seed 
extracts produced considerable inhibition of 
CYP1A2 activity. It has been shown that 
black cohosh exhibited a potent inhibition 
of CYP3A4 (Sevior et al., 2010; Tsukamoto 
et al., 2005). A recent in vitro study has al-
so reported that the active constituents of 
black cohosh triterpene glycosides were 
weakly, while fukinolic acid and cimi-
cifugic acids A and B strongly inhibited 
CYP1A2 and CYP3A4 isozymes (Huang et 
al., 2010). Interactions between black 
cohosh and CYP3A are rather complicated. 
It has been demonstrated that induction of 
mouse Cyp3a11 is species-specific and in-
volved only mouse PXR, not the human 
counterpart (Pang et al., 2011). Thus, the 
incidence of herbal drug interaction in pati-
ents taking black cohosh may not be media-
ted by human PXR and CYP3A4. A study 
in healthy volunteers examined the effects 
of black cohosh root extract on CYP1A2 
metabolism using caffeine as a probe drug 
(Gurley et al., 2005a). They found that 
black cohosh did not inhibit CYP1A2 activ-
ity. Results on BC obtained from this study 
have shown that BC caused very weak to 
mild inhibition of human CYP1A2 activity. 
Contradiction between our results and those 
from Gurley and co-workers (Gurley et al., 
2005a) could be related to the fact that their 
study was done in vivo (healthy volunteers) 
whereas ours was an in vitro study. Also the 
inhibition of human CYP1A2 activity de-
tected in this study was mild (< 25 %) and 
this may not be seen as a significant effect 
in an in vivo study. These may suggest that 
taking black cohosh concomitantly with 
prescription drugs metabolized by CYP1A2 
is unlikely to cause herbal drug interaction. 
Con-suming black cohosh as dietary supp-
lement may not have a benefit for protec-
tion of cancer if its cause resulted from bio-
activation via CYP1A2.  
Effect of ginseng on the activity of hu-
man CYP1A2 was investigated; the results 
obtained from the present study show little 
to moderate inhibitory effect. Of nine 
brands tested, only two products Spring 
Valley (34.1 % inhibition) and Solarays 
(44.6 % inhibition) caused mode-rate inhi-
bition of CYP1A2. These results suggest 
that ginseng herbal supplements have little 
effect on human CYP1A2 activity. How-
ever, a moderate inhibitory effect can be 
produced by some specific brands of gin-
seng products. This may be resulted from 
variation in active ingredients of ginseng in 
different brand products. Our findings sho-
wing little inhibitory effect of ginseng on 
the activity of human CYP1A2 are in ag-
reement with those reported previously 
(Gurley et al., 2005b). In their study, 28 
days of ginseng supplementations in elderly 
volunteers did not appear to affect the acti-
vity of CYP1A2. In addition, an in vitro 
study was carried out to determine the 
effect of ginseng’s active components 
ginsenosides and eleuthe-rosides on the ca-
talytic activity of c-DNA expressed CYP 
isoforms. It was found that these active 
components of ginseng are not likely to in-
hibit the metabolism of drugs in which the 
primary route of elimination is mediated by 
P450 enzymes including CYP1A2 (Hender-
son et al., 1999). A recent study in rats has 
shown that after pretreatment with ginseng 
for 1 week, an induction effect on CYP1A2 
was observed as there was a significant in-
crease in clearance of the CYP1A2 probe 
drug caffeine, compared with that of the 
control group (Liu et al., 2011). Results 
with Western blot analysis also revealed the 
upregulation of the CYP1A2 protein ex-
pression induced by ginseng pretreatment. 
Similar to ginseng, the effect of GSE 
dietary supplements on human CYP1A2 
activity was mild. Six of nine GSE brands 
investigated have shown to inhibit CYP1A2 
activity moderately (< 27 % inhibition). 
These results are similar to those observed 
in an in vitro experiment showing that low 
concentrations of GSE (normalized to 
1 mM catechin) slightly activated, whereas 
high concentration of GSE (10 mM cate-
chin) moderately inhibited (approximately 
24 % inhibition) the activity of human 
CYP1A2 (Etheridge et al., 2007). An in 
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vitro study has demonstrated that GSE and 
other grape phytochemicals were strong 
inhibitors of human CYP1A2 enzyme 
(Kowalczyk et al., 2009). This is incon-
sistent with our results and may be ex-
plained by differences in experimental con-
ditions such as concentrations of GSE and 
in vitro systems used.  
Our finding with green tea extract 
(GTE) suggests that most of GTE products 
inhibited the activity of human CYP1A2 as 
nine of twelve brands studied have demon-
strated to cause moderate to strong inhibi-
tion of CYP1A2 (Figure 4). These results 
are in agreement with those observed pre-
viously in which it has been shown that 
green tea polyphenols (e.g. epicatechin, epi-
catechin gallate and epigallocatechin) ap-
peared to inhibit the activity of CYP1A2 
(Dhawan et al., 2002). Green tea had com-
plex effects upon CYP1A1 activity in rat 
liver microsomes, which consisted of an 
initial activation of the enzyme at low con-
centrations followed by inhibition at higher 
concentrations (Anger et al., 2005). This 
observation may explain our results with 
variable inhibitory effect on human 
CYP1A2 produced by different brands of 
green tea supplement products. These prod-
ucts are likely to contain different contents 
of active ingredients of green tea. Thus, dif-
ferent concentrations of green tea’s active 
constituents were presented in the green tea 
extracts obtained from different brand 
products. A recent report has found that the 
most abundant component in green tea, i.e., 
(-) epigallocatechin-3-gallate (EGCG) did 
not affect the activity of CYP1A2 (Bothe et 
al., 2011). An in vivo study in rats has 
demonstrated that after 4 days pretreatment 
with GTE, there was an induction of 
CYP1A2 as the hepatic CYP1A2 levels 
were increased by approximately 2-fold, 
while the enzyme activity increased slightly 
i.e., by 10 % of control (Jang et al., 2005). 
Also a previous study in healthy volunteers 
found that a 4 weeks pretreatment with 
green tea catechin did not alter the pheno-
typic index of CYP1A2 (Chow et al., 
2006). It was likely that EGCG and epicat-
echin-3-gallate would be the major compo-
nents responsible for the inhibitory effect of 
GTE (Anderson et al., 2003; Chow et al., 
2006). The role of green tea in cancer pre-
vention, meaning the ability to delay the 
onset of the carcinogenic process, has be-
come an intense area of research over the 
past year (Netsch et al., 2006). The drinking 
of green tea is particularly popular in Asian 
cultures, and its connection with human 
health benefits has resulted in the inclusion 
of GTEs as common botanical ingredients 
in dietary supplements, nutraceuticals, and 
functional foods (Henning et al., 2006). 
The inhibitory effect produced by each 
herbal supplement appeared to vary be-
tween brands of the products. The differ-
ences in the inhibitory effect of herbal sup-
plementary products investigated on human 
CYP1A2 could be associated with/or likely 
to be due to the variation in active ingredi-
ents in these herbal supplements. This find-
ing is in accordance with our previous study 
showing a similar observation in which 
there was a large variation in inhibitory ef-
fect of herbal supplements on human 
CYP3A4 (Wanwimolruk et al., 2009). Of 
note is that human CYP3A4 is the most 
abundant isoform and metabolizes more 
than 40 % of prescription drugs, thus drug-
drug interactions with CYP3A4 is extreme-
ly important and this enzyme activity is also 
affected by herbal and plant extracts 
(Guengerich 1999; Shi and Klotz, 2012). 
Although the active ingredients in each 
herbal supplement was not measured in this 
study (because of complexity and difficulty 
of the analytical assays), our findings are in 
harmony with earlier studies which have 
demonstrated a great variation in the active 
ingredients in many herbal products. These 
examples include the following findings. 
Inconsistencies between actual product 
composition and labeled content have been 
reported with ginseng, echinacea, St. John’s 
wort, Ma Huang and androstenedione (Cui 
et al., 1994; Draves and Walker, 2003; 
Green et al., 2001; Haller et al., 2004; 
Harkey et al., 2001). Of 25 commercial gin-
seng preparations analyzed, the content of 
active ingredients (ginsenosides and eleu-
therosides) differed significantly from la-
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beled amounts (Harkey et al., 2001). The 
contents were found to range from 11 % to 
328 % of the labeled content. There was 
also significant product-to-product variabil-
ity. Testing of 28 brands of St. John’s wort 
capsules revealed large variations in the to-
tal content of active ingredients (sum of hy-
pericin and pseudohypericin). The percent-
age of label claim varied from 0 % to 
109 % (Draves and Walker, 2003). Like-
wise, the Good Housekeeping Institute has 
also found a 17-fold difference in the hy-
pericin content and a 13-fold difference in 
pseudohypericin content present in 10 St. 
John’s wort preparations tested (Good 
Housekeeping Institute, 1998). Our findings 
suggest that the benefit of taking these 
herbal supplements as antioxidants will be 
dependent upon the brand of product con-
sumed. Without exclusive quality control 
such as standardizing active ingredients in 
dietary supplement products, consumers are 
not likely to gain benefits from taking these 
natural dietary supplement products. 
In summary, the results in the current 
study demonstrate that there are small and 
large variations of the inhibitory effect of 
herbal dietary supplements on human 
CYP1A2. Particularly for grape seed ex-
tract (even though its effect was less pro-
nounced than that of green tea extract) and 
green tea extract supplements, the varia-
tions (15-fold to 16-fold) among different 
brands were extraordinary. This questions 
the quality of the dietary supplements that 
many patients take presuming these dietary 
supplement products to be safe. In addition, 
it supports the recommendation earlier sug-
gested by other investigators (Cui et al., 
1994; Draves and Walker, 2003; Foster et 
al., 2005; Good Housekeeping Institute, 
1998; Green et al., 2001; Henning et al., 
2006) that trustworthy labeling information 
and standardized manufacturing practices 
by means of biological and phytochemical 
assays be put in place for the quality control 
of herbal/botanical dietary supplements. 
Moreover, lack of inhibitory effects of 
black cohosh, grape seed extract and gin-
seng on CYP1A2 activity implies that there 
is no clinically significant herbal drug in-
teraction as a result of enzyme inhibition to 
be expected upon coadministration of these 
herbal supplements with prescription drugs 
which are metabolized by CYP1A2. How-
ever, from our results we cannot exclude 
that coadministration of green tea extract 
supplements with CYP1A2 drugs may 
cause an increase in the concentrations of 
such drugs. Clinical studies are warranted 
to refine this issue. Conversely, a possible 
in vivo inhibition of CYP1A2 by green tea 
extract might provide a beneficial protec-
tion against cancer, caused by the metabolic 
activation of CYP1A2. 
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